Atyr Pharma Inc. (NASDAQ: LIFE) stock gained by 34.84% in the current market trading session. aTyr is a biotherapeutics firm focused on discovering and developing new medicines based on novel biological pathways. The extracellular functionality and signaling pathways of tRNA synthetases which is a recently found area of biology are the focus of aTyr’s research and development initiatives.
LIFE stock’ Current Update
aTyr Pharma reported good findings from a Phase 1b/2a double-blind, placebo-controlled clinical trial of ATYR1923, its primary treatment candidate, in 37 patients with pulmonary sarcoidosis which is a common form of interstitial lung disease. At all doses, ATYR1923 was shown to be secure and very well accepted, with no drug-related major negative events or signs of immunogenicity. ATYR1923 also showed a consistent dosage response on key efficacy endpoints and benefits when compared to placebo in the research. Steroid reduction, lung function, sarcoidosis symptom assessments, and inflammatory biomarkers were all part of the response.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Pulmonary sarcoidosis is an inflammatory illness that causes granulomas, or clusters of inflammatory cells, to grow in one or maybe more organs of the body. The prognosis for pulmonary sarcoidosis, which affects about 200,000 people in the United States, ranges from benign and self-limiting to chronic, severe disease, lifelong loss of lung function, and death. Corticosteroids and other immunosuppressive medicines are currently available treatments, but they have little efficacy and are linked with substantial adverse effects that many patients cannot endure long-term.
The Phase 1b/2a study involved 37 patients with pulmonary sarcoidosis in a randomized, double-blind, placebo-controlled, multiple-ascending dose clinical trial. The experiment had three groups that were given ATYR1923 or placebo at dosages of 1.0 mg/kg, 3.0 mg/kg, and 5.0 mg/kg intravenously every month for six months. The study’s main goal was to evaluate the efficacy, acceptability, immunogenicity, and pharmacokinetic profile of different dosages of ATYR1923 to placebo. The possible steroid-sparing effects of ATYR1923, as well as other exploratory efficacy tests, such as lung function, were secondary targets